Biotek-snakken — Juni 2021
-
Avanza køber godt nok XBrane aktier med arme og ben i øjeblikket….Det ser rigtig godt ud. Bare det ikke går for hurtigt, så vi får en rutschetur nedad igen.
-
Targovax’s ONCOS-102 mesothelioma 24-month data shows class-leading median overall survival -https://www.targovax.com/en/targovaxs-oncos-102-mesothelioma-24-month-data-shows-class-leading-median-overall-survival/
-
Meldingen var ventet, men jo super data
"mOS) for first-line treatment with ONCOS-102 plus chemotherapy will be between 21,9 and 25 months, compared with mOS of 13,5 months in the chemotherapy-only control group
Broad and powerful immune activation". -
Pharmia ny præsentationsvideo. Absolut værd at se. https://www.youtube.com/watch?app=desktop&v=V83ml_Q7_SU
-
Disclaimer. Jeg købte mig ind i selskabet to år før børsnotering i marts 2021.
-
Orphazyme nyt ?
-
Tak for Acarix beregningerne Jazzz….Lad os håbe det holder.
Der må simpelthen være nogen, som har "hørt" noget fra FDA....sært.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind